|
GVS S.p.A. is a manufacturer of filtration solutions for the healthcare, life sciences, energy, mobility, and health and safety sectors. Founded in 1979, the company operates through four main divisions: Healthcare & Life Sciences, Energy & Mobility, Health & Safety, and Transfusion Medicine. Its product portfolio includes blood filters, infusion devices, stopcocks, microfiltration technologies for bioprocessing and diagnostics, automotive filtration components, and personal protective equipment. The group serves global markets with manufacturing plants in Italy, the United Kingdom, Brazil, the United States, China, Mexico, Romania, and Puerto Rico, alongside commercial offices worldwide. Key subsidiaries and acquired entities include Valplast, RPB, Shanghai Transfusion Technology, Haemotronic, and Haemonetics’ Whole Blood business. GVS listed on the Italian Stock Exchange in 2020. Summarised from the company's own disclosures, fiscal year ended Dec 2025 |
Industry Medical Instruments & Supplies | Homepage gvs.com |
| Sector Healthcare | IR page gvs.com/en | |
|
Tags
blood filtration, infusion devices, microfiltration, automotive filtration, personal protective equipment, transfusion medicine, bioprocessing, pharmaceutical packaging, Valplast, RPB, Shanghai Transfusion Technology, Haemotronic, Haemonetics, GVS MedTech
|
Press page gvs.com/en/news |
Metrics
| Valuation | |
|---|---|
| Market cap | € 819.829M |
| Market cap (USD) | $ 919.357M |
| P/E | 44.48 |
| PEG | — |
| P/BV | 1.88 |
| P/S | 1.89 |
| P/OCF | 10.95 |
| P/FCF | 39.46 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 4.1% |
| ROI | 5.0% |
| ROIC | 5.0% |
| Profit margin | 4.3% |
| Growth | |
|---|---|
| Revenue growing | No |
| Profits growing | No |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | -8.5% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | Yes |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 60 |
| Quality score | -41.2% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||
| Trade receivables (EUR) | 52.1M | 53M | 72.9M | 54.1M | 55.4M | 50.8M |
| ↳ YoY growth | +1.7% | +37.7% | -25.8% | +2.3% | -8.3% | |
| ↳ 5y CAGR | -0.5% | |||||
| Lease liabilities (EUR) | 8.97M | 11.5M | 25.2M | 20.5M | 22.2M | 22.3M |
| Cash and deposits (EUR) | 125M | 137M | 135M | 191M | 103M | 78.7M |
| Intangible assets (EUR) | — | — | — | 472M | 473M | 434M |
| Right-of-use assets (EUR) | 8.44M | 10.4M | 23M | 20.2M | 23.4M | 25.2M |
| Cash flow detail | ||||||
| Operating cash flow (EUR) | 114M | 55.5M | 76.1M | 102M | 97.1M | 74.9M |
| Purchases of property, plant and equipment (EUR) | -27.3M | -19.4M | -17.8M | -21.3M | -29.2M | -54.1M |
| Purchases of intangible assets (EUR) | -4.06M | -3.76M | -5.02M | -6.86M | -8.15M | -9.51M |
| Change in receivables (cash effect) (EUR) | -6.17M | -4.67M | -11.9M | 19.2M | -1.2M | -1.56M |
| Change in inventories (cash effect) (EUR) | -21M | -9.53M | 3.14M | 14.6M | 3.19M | -13.4M |
| Change in payables (cash effect) (EUR) | 18.2M | -6.41M | 13.8M | -17.4M | 4.82M | 7.22M |
| Dividends paid (cash effect) (EUR) | -1.68M | -22.7M | 0.00 | — | — | — |
| Interest paid (cash effect) (EUR) | -4.96M | -2.94M | -4.9M | -17.9M | -18.2M | -12.4M |
| Income taxes paid (cash effect) (EUR) | -16.3M | -32.6M | 9.85M | 10.5M | 15M | 14.5M |
| Operating cash flow before change in receivables (EUR) | 120M | 60.2M | 88M | 82.4M | 98.3M | 76.5M |
| Free cash flow (OCF - PPE - intangibles) (EUR) | 82.7M | 32.3M | 53.3M | 73.4M | 59.8M | 11.3M |
| Income detail | ||||||
| Total comprehensive income (EUR) | 69.3M | 76.2M | 31.7M | 5.23M | 39.9M | -6.64M |
| Comprehensive income to owners (EUR) | 69.3M | 76.1M | 31.7M | 5.28M | 39.9M | -6.6M |
| Provision for credit losses (EUR) | 335,000 | 462,000 | 506,000 | 594,000 | 696,000 | 240,000 |
| Credit cost ratio (credit losses / average receivables) (%) | — | 0.9% | 0.8% | 0.9% | 1.3% | 0.5% |
| Reported | May 30, 2023 | May 30, 2023 | May 30, 2023 | Apr 23, 2025 | Apr 23, 2025 | Apr 29, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpRegulated releases stored at eMarket Storage and 1INFO, newest first, titles as filed, own-share transactions, internal dealing, holdings and voting-rights notices included. The link opens the filed PDF. Press releases from the company's own website, newest first.

-
GVS Transfusion Medicine to Exhibit at the AABB Annual Meeting 2026
Share
2026/10/08
GVS will once again participate in the AABB Annual Meeting, one of the most important international events dedicated to blood banking, transfusion medicine and biotherapies, taking place in Atlanta, Georgia, from October 17 to 19, 2026. The event brings together healthcare professionals, researchers, industry leaders and decision-makers from around the world to explore the latest developments shaping the future of the sector.
During the exhibition, the GVS Transfusion Medicine team will be available to meet customers, partners and industry professionals, presenting the company's comprehensive portfolio of filtration and blood management solutions designed to support safety, efficiency and performance across transfusion workflows.
The AABB Annual Meeting represents a key opportunity to engage with the global transfusion medicine community, exchange knowledge and discuss emerging challenges and trends affecting blood collection, processing and patient care. The 2026 edition will feature educational sessions, scientific presentations and networking opportunities focused on the latest advances in blood banking, transfusion medicine and biotherapies.
As a long-standing partner to healthcare institutions and blood centers worldwide, GVS remains committed to supporting innovation and advancing technologies that contribute to safer and more efficient transfusion practices.
We look forward to welcoming visitors at our booth and discussing how GVS solutions can help address the evolving needs of the transfusion medicine field.
AABB Annual Meeting 2026
October 17-19, 2026
Georgia World Congress Center, Atlanta, Georgia (USA)
Share
Related articles
-
World Blood Donor Day 2026: One Drop of Humanity
Transfusion Medicine
Find out more -
GVS at ISBT 2026: Integrated Solutions for Collection, Processing and Transfusion
Transfusion Medicine
Find out more -
Covina: a Strategic Hub for GVS Transfusion Medicine
Transfusion Medicine
Find out more -
SQ40: High Flow Blood Filtration Designed for Performance in Transfusion Medicine
Transfusion Medicine
Find out more
-
Company Company
-
ESG ESG
-
Industries Industries
-
Investor Relations Investor Relations
-
Governance Governance
-
Follow us:
Copyright 2022 GVS S.p.A. VAT n. 00644831208
- Company Info
- Privacy
Go back to the global website Select a country or territory to show the localized content:
Continue
To access the localized content, select the website associated with the Division of your interest:
MedTech
Transfusion Medicine
Life Sciences
Safety
Energy & Mobility
Go back to the global website
Type your search text here
Search
Via Roma, 50 - 40069 Zola Predosa (Bologna) - Italy
Tel. +39 051 6176311 | Fax +39 051 6176200 | e-mail: [email protected]
Cap. Soc. € 1.750.000,00 interamente versato | C.F. 03636630372
R.E.A 0305386/BO | Reg. Imprese 45539/BO | Mecc. BO 012048
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding GVS S.p.A.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| AVDS | 0.01% | 6,208 | $ 40.989K | Nov 16, 2026 |
| DFIS | 0.01% | 56,528 | $ 391.604K | Nov 12, 2026 |
| DXIV | 0.01% | 2,052 | $ 14.215K | Nov 12, 2026 |
| DFIC | 0.00% | 32,162 | $ 222.806K | Nov 12, 2026 |
| DFAX | 0.00% | 23,527 | $ 162.986K | Nov 12, 2026 |
| DFAI | 0.00% | 17,556 | $ 121.621K | Nov 12, 2026 |
| DISV | 0.00% | 2,481 | $ 17.187K | Nov 12, 2026 |


























